Tinea Nigra 

  • Author: Robert A Schwartz, MD, MPH; Chief Editor: William D James, MD   more...
 
Updated: May 13, 2011
 

Background

Tinea nigra is an uncommon superficial dermatomycosis usually caused by Hortaea werneckii, formerly known as Phaeoannellomyces werneckii, (formerly classified as Exophiala werneckii and Cladosporium werneckii).[1] Tinea nigra may also be due to Stenella araguata, first described and named Cladosporium castellanii in 1973.[2] Tinea nigra appears as a hyperpigmented macule, which usually occurs on the palms. The soles and, more rarely, other areas of the body, can also be affected.

Cequeira first described tinea nigra in 1891, calling the infection keratomycosis nigricans palmaris. In 1921, Horta isolated the pathogen and gave it its original name, C werneckii.

Although P werneckii has been established as the causative fungus in most cases of tinea nigra, other species of dematiaceous fungi, such as S araguata, may produce a similar clinical picture.

A Cladophialophora strain, allegedly a new species, Cladophialophora saturnica, has been described that caused an interdigital tinea nigra – like lesion in a HIV-positive Brazilian child, successfully treated with oxiconazole.[3]

Next

Pathophysiology

Tinea nigra is a superficial mycosis of the stratum corneum. Infection is believed to occur as a result of inoculation from a contamination source such as soil, sewage, wood, or compost subsequent to trauma in the affected area.

Typically, the incubation period for tinea nigra is 2-7 weeks, although in experimental inoculation, the incubation period was 20 years.[4] The fungus exhibits lipophilic adhesion to human skin; it is exclusively found in the stratum corneum and does not extend into the stratum lucidum.

P werneckii receives nourishment from its use of decomposed lipids. Its tolerance to an environment with a high salt concentration and a low pH allows the fungus to thrive in human skin. It has been isolated from the hypersaline waters of salterns as one of the predominant species of a group of halophilic and halotolerant melanized yeastlike fungi.[5] P werneckii has distinct mechanisms of adaptation to high-salinity environments that are not seen in salt-sensitive and only moderately salt–tolerant fungi.

A pigmentary change in the skin results in a dark-colored macule due to the accumulation of a melaninlike substance in the fungus.

Previous
Next

Epidemiology

Frequency

United States

Tinea nigra is relatively uncommon in the United States. However, numerous cases are reported in the dermatologic literature. Tinea nigra typically affects people who reside in the coastal states such as Florida, Texas, Alabama, Louisiana, Virginia, and North Carolina. Although cases of tinea nigra are also reported in patients from northern and inland regions of the United States, including New York City, Chicago, and Boston, patients often report a history of foreign travel, frequently to the Caribbean Islands.[6]

International

Tinea nigra is not uncommon in tropical regions of Central America, South America, Africa, and Asia. Epidemiologic studies of skin diseases in schoolchildren performed by direct inspection using dermatologists in Magong, Penghu, Republic of China on the island of Formosa found the prevalence of fungal infection, including tinea nigra, tinea versicolor, and tinea corporis, to be 0.24% (95% confidence interval, 0.07-0.41%).[7] Tinea nigra may present as an imported infection from endemic areas into temperate climate regions.[6]

Mortality/Morbidity

Although the appearance of tinea nigra may be alarming because of its uncommon occurrence and its potential confusion with a more serious medical disorder (eg, malignant melanoma[8, 9] ), tinea nigra is a benign disease that is easily curable.

Race

Tinea nigra appears to occur less often in the black population than in others, although this observation may reflect impaired recognition of the disease.

Sex

The female-to-male predilection for tinea nigra is 3:1.

Age

Tinea nigra most often occurs in pediatric and adolescent populations; however, individuals of any age may be affected. In a study of 12 patients in Venezuela, it was found to be more prevalent among young people with fair skin aged 3-28 years who visited beaches.[2]

Previous
 
 
Contributor Information and Disclosures
Author

Robert A Schwartz, MD, MPH  Professor and Head, Dermatology, Professor of Pathology, Pediatrics, Medicine, and Preventive Medicine and Community Health, University of Medicine and Dentistry of New Jersey-New Jersey Medical School

Robert A Schwartz, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, and Sigma Xi

Disclosure: Nothing to disclose.

Coauthor(s)

George Kihiczak, MD  Clinical Associate Professor, Department of Dermatology, New Jersey Medical School and University Hospital

George Kihiczak, MD is a member of the following medical societies: American Academy of Dermatology, American Medical Association, and Medical Society of New Jersey

Disclosure: Nothing to disclose.

Specialty Editor Board

Neil Shear, MD  Professor and Chief of Dermatology, Professor of Medicine, Pediatrics and Pharmacology, University of Toronto Faculty of Medicine; Head of Dermatology, Sunnybrook Women's College Health Sciences Center and Women's College Hospital, Canada

Neil Shear, MD is a member of the following medical societies: American Academy of Dermatology, American Society for Clinical Pharmacology and Therapeutics, Canadian Dermatology Association, Canadian Medical Association, Ontario Medical Association, and Royal College of Physicians and Surgeons of Canada

Disclosure: Nothing to disclose.

David F Butler, MD  Professor of Dermatology, Texas A&M University College of Medicine; Chair, Department of Dermatology, Director, Dermatology Residency Training Program, Scott and White Clinic, Northside Clinic

David F Butler, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, American Society for Dermatologic Surgery, American Society for MOHS Surgery, Association of Military Dermatologists, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Paul Krusinski, MD  Director of Dermatology, Fletcher Allen Health Care; Professor, Department of Internal Medicine, University of Vermont College of Medicine

Paul Krusinski, MD is a member of the following medical societies: American Academy of Dermatology, American College of Physicians, and Society for Investigative Dermatology

Disclosure: Nothing to disclose.

Catherine M Quirk, MD  Clinical Assistant Professor, Department of Dermatology, University of Pennsylvania

Catherine M Quirk, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Dermatology

Disclosure: Nothing to disclose.

Chief Editor

William D James, MD  Paul R Gross Professor of Dermatology, University of Pennsylvania School of Medicine; Vice-Chair, Program Director, Department of Dermatology, University of Pennsylvania Health System

William D James, MD is a member of the following medical societies: American Academy of Dermatology and Society for Investigative Dermatology

Disclosure: Elsevier Royalty Other

Additional Contributors

The authors and editors of eMedicine gratefully acknowledge the contributions of previous author, Vinay Arya, MD, to the development and writing of this article.

References
  1. Schwartz RA. Superficial fungal infections. Lancet. Sep 25-Oct 1 2004;364(9440):1173-82. [Medline].

  2. Perez C, Colella MT, Olaizola C, Hartung de Capriles C, Magaldi S, Mata-Essayag S. Tinea nigra: report of twelve cases in Venezuela. Mycopathologia. Oct 2005;160(3):235-8. [Medline].

  3. Badali H, Carvalho VO, Vicente V, et al. Cladophialophora saturnica sp. nov., a new opportunistic species of Chaetothyriales revealed using molecular data. Med Mycol. Feb 2009;47(1):51-62. [Medline].

  4. Blank H. Tinea nigra: a twenty-year incubation period?. J Am Acad Dermatol. Jul 1979;1(1):49-51. [Medline].

  5. Lenassi M, Vaupotic T, Gunde-Cimerman N, Plemenitas A. The MAP kinase HwHog1 from the halophilic black yeast Hortaea werneckii: coping with stresses in solar salterns. Saline Systems. 2007;3:3. [Medline].

  6. Rezusta A, Gilaberte Y, Betran A, Gene J, Querol I, Arias M, et al. Tinea nigra: a rare imported infection. J Eur Acad Dermatol Venereol. Jan 2010;24(1):89-91. [Medline].

  7. Chen GY, Cheng YW, Wang CY, Hsu TJ, Hsu MM, Yang PT, et al. Prevalence of skin diseases among schoolchildren in Magong, Penghu, Taiwan: a community-based clinical survey. J Formos Med Assoc. Jan 2008;107(1):21-9. [Medline].

  8. Hall J, Perry VE. Tinea nigra palmaris: differentiation from malignant melanoma or junctional nevi. Cutis. Jul 1998;62(1):45-6. [Medline].

  9. Tseng SS, Whittier S, Miller SR, Zalar GL. Bilateral tinea nigra plantaris and tinea nigra plantaris mimicking melanoma. Cutis. Oct 1999;64(4):265-8. [Medline].

  10. Uezato H, Gushi M, Hagiwara K, Kayo S, Hosokawa A, Nonaka S. A case of tinea nigra palmaris in Okinawa, Japan. J Dermatol. Jan 2006;33(1):23-9. [Medline].

  11. Zalaudek I, Giacomel J, Cabo H, Di Stefani A, Ferrara G, Hofmann-Wellenhof R, et al. Entodermoscopy: a new tool for diagnosing skin infections and infestations. Dermatology. 2008;216(1):14-23. [Medline].

  12. Paschoal FM, de Barros JA, de Barros DP, de Barros JC, Filho CD. Study of the dermatoscopic pattern of tinea nigra: report of 6 cases. Skinmed. Nov-Dec 2010;8(6):319-21. [Medline].

  13. Tilak R, Singh S, Prakash P, Singh DP, Gulati AK. A case report of tinea nigra from North India. Indian J Dermatol Venereol Leprol. Sep-Oct 2009;75(5):538-9. [Medline].

  14. Burke WA. Tinea nigra: treatment with topical ketoconazole. Cutis. Oct 1993;52(4):209-11. [Medline].

  15. Marks JG Jr, King RD, Davis BM. Treatment of tinea nigra palmaris with miconazole. Arch Dermatol. Mar 1980;116(3):321-2. [Medline].

  16. Shannon PL, Ramos-Caro FA, Cosgrove BF, Flowers FP. Treatment of tinea nigra with terbinafine. Cutis. Sep 1999;64(3):199-201. [Medline].

  17. Babel DE, Pelachyk JM, Hurley JP. Tinea nigra masquerading as acral lentiginous melanoma. J Dermatol Surg Oncol. May 1986;12(5):502-4. [Medline].

Previous
Next
 
Tinea nigra, evident as a painless cluster of brown-to-black macules. Courtesy of Dr. Peter Santalucia.
Tinea nigra, showing hyperkeratosis and mild acanthosis. A scant amount of perivascular lymphocytic infiltrate may be found in the papillary and subpapillary layers of the dermis (hematoxylin and eosin stain). Courtesy of Thomas N. Helm, MD.
Tinea nigra, with histologic section demonstrating periodic acid-Schiff–positive septate hyphae within the stratum corneum. Courtesy of Thomas N. Helm, MD.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.